poisar

Stock

Atrium Therapeutics, Inc. RNA

$13.95+0.94%

Overview

RNA market data

Price History

RNA price chart · 1M
O
13.79
H
14.06
L
13.70
C
13.95
Vol
2,733.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$13.79
Previous Close
$13.82
Day High
$14.06
Day Low
$13.70
52 Week High
$14.07
52 Week Low
$11.13
7 Day Return
+3.56%
30 Day Return
+21.09%
90 Day Return
+7.39%
1 Year Return
+7.39%
Daily Notional Volume
$38.1K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.89
Diluted earnings per share over the trailing twelve months.
Beta
1.07
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-172.9%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$11.13 – $73.06
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $210.9M · P/B 0.76 · P/S 5.51.

Company News

8 captured
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price TargetBenzinga · Aug 14, 2026, 5:27 PM
8-K filing — Atrium Therapeutics, Inc. (RNA)SEC EDGAR · Aug 13, 2026, 8:50 PM
Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M EstimateBenzinga · Aug 13, 2026, 8:49 PM
Atrium Therapeutics Announces $15M Milestone Payment From Bristol Myers Squibb On Delivery Of Second Lead Compound In Undisclosed Cardiology IndicationBenzinga · Aug 13, 2026, 12:05 PM
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For ThursdayBenzinga · Aug 6, 2026, 2:12 PM
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25Benzinga · Aug 6, 2026, 11:12 AM
Atrium Therapeutics Says FDA Clears IND Application Allowing It To Move Forward With Corventis Phase 1/2 Clinical Trial To Evaluate ATR 1072 For Treatment Of PRKAG2 SyndromeBenzinga · Jul 14, 2026, 10:33 AM
Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25Benzinga · Jun 18, 2026, 12:55 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock